Navigation Links
Medarex Announces 2008 Third Quarter Financial Results
Date:10/30/2008

g statements preceded by, followed by, or that include the words "potential"; "preliminary"; or similar statements are forward-looking statements. Medarex disclaims any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, the need for additional capital, compliance with regulatory requirements, risks associated with the use of hazardous substances and risks associated with the enforceability of our patents, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo, UltiMAb(R) and HuMAb(TM) are trademarks of Medarex, Inc. All rights are reserved.

MEDAREX, INC.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

(unaudited) (unaudited)

2008 2007 2008 2007

<
'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2
... (Nasdaq: NKTR ) announced today that Bharatt ... Operating Officer and Head of the,PEGylation Business Unit. ... the PEGylation Business Unit, including research,and manufacturing, as ... also,serve as Chairman of Nektar India Pvt., Ltd. ...
... 22 Edwards Lifesciences,Corporation (NYSE: EW ... of heart valves,today announced the opening of ... North Crescent, Singapore. The state-of-the-art facility produces,Edwards, ... also serves as the headquarters for Edwards, ...
... Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: ... CDX-110, being developed for the treatment of Glioblastoma,Multiforme ... presentation at the 44th,Annual Meeting of the American ... be held at McCormick Place in Chicago from ...
Cached Biology Technology:Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3Edwards Lifesciences Opens New Singapore Heart Valve Facility 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
(Date:9/17/2014)... professor and his doctoral student have designed a device ... collected from fog and dew., The device could provide ... around the globe., Cheng Luo, professor in the Mechanical ... in the same College of Engineering department, published "Bioinspired ... ACS, (American Chemical Society) Applied Materials & ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2
... Abroad ReportedWALL, N.J., Jan. 19 BIO-key International, ... finger-based biometric identification and wireless public safety solutions, ... the media on its fingerprint biometrics identification solutions ... 8th edition of This Week in Consumer ...
... latest American Chemical Society (ACS) Weekly PressPac from the Office ... journals and Chemical & Engineering News . Please credit ... source for this information. ARTICLE #1 FOR IMMEDIATE RELEASE ... , Analytical Chemistry In a macabre discovery ...
... SHORES, Calif., Jan. 14 Communication Intelligence Corporation ... leading supplier of electronic signature solutions for business ... recognized leader** in biometric signature verification will be ... an independent technology and market research company that ...
Cached Biology News:BIO-key(R) Fingerprint Biometrics Media Spotlights 2BIO-key(R) Fingerprint Biometrics Media Spotlights 3American Chemical Society's weekly PressPac -- Jan. 14, 2009 2American Chemical Society's weekly PressPac -- Jan. 14, 2009 3American Chemical Society's weekly PressPac -- Jan. 14, 2009 4American Chemical Society's weekly PressPac -- Jan. 14, 2009 5American Chemical Society's weekly PressPac -- Jan. 14, 2009 6CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 2CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 3CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 4
...
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
... Cells and TriEx Insect Cell Medium are ... constructs. This cell/medium combination has been selected ... high protein expression levels observed specifically with ... note that our Ready-Plaque Sf9 Cells and ...
...
Biology Products: